ARAF is an inclusion eligibility criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain ARAF status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ATM is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRAF is an inclusion eligibility criterion in 10 clinical trials for glioma, of which 7 are open and 3 are closed. Of the trials that contain BRAF status and glioma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CRKL is an inclusion eligibility criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 3 clinical trials for glioma, of which 1 is open and 2 are closed. Of the trials that contain EGFR status and glioma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [3].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains FGFR1 status and glioma as inclusion criteria, 1 is phase 2 (0 open) [3].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 status and glioma as inclusion criteria, 1 is phase 2 (0 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and glioma as inclusion criteria, 1 is phase 2 (0 open) [3].

H3F3A is an inclusion eligibility criterion in 3 clinical trials for glioma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and glioma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

HGF is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains HGF status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

HRAS is an inclusion eligibility criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 13 clinical trials for glioma, of which 11 are open and 2 are closed. Of the trials that contain IDH1 status and glioma as inclusion criteria, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 2 are no phase specified (2 open) [3].

IDH2 is an inclusion eligibility criterion in 8 clinical trials for glioma, of which 6 are open and 2 are closed. Of the trials that contain IDH2 status and glioma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 5 are phase 2 (4 open) [3].

KIAA1549 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains KIAA1549 status and glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 3 clinical trials for glioma, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and glioma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].

MAP2K1 is an inclusion eligibility criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K2 status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K4 status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP3K1 status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain MAPK1 status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MET is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains MET status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and glioma as inclusion criteria, 1 is no phase specified (1 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

NF1 is an inclusion eligibility criterion in 5 clinical trials for glioma, of which 3 are open and 2 are closed. Of the trials that contain NF1 status and glioma as inclusion criteria, 4 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 3 clinical trials for glioma, of which 3 are open and 0 are closed. Of the trials that contain NRAS status and glioma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains PDGFRA status and glioma as inclusion criteria, 1 is phase 2 (0 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain RAF1 status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SRC is an inclusion eligibility criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain SRC status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

TACC1 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains TACC1 status and glioma as inclusion criteria, 1 is phase 2 (0 open) [3].

TACC3 is an inclusion eligibility criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains TACC3 status and glioma as inclusion criteria, 1 is phase 2 (0 open) [3].